Comparative Pharmacology
Head-to-head clinical analysis: COLESTID versus WELCHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTID versus WELCHOL.
COLESTID vs WELCHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.
5-10 g orally once or twice daily, maximum 30 g/day.
Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.
None Documented
None Documented
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable; colesevelam acts locally in the gastrointestinal tract and is not absorbed systemically. Terminal half-life is not measurable in conventional pharmacokinetic sense due to negligible systemic absorption.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Primarily fecal as unchanged drug (approximately 85%), with less than 0.5% renal excretion of absorbed drug; no biliary excretion due to non-absorbed nature.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant